Standard BioTools Inc. (Nasdaq: LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and…
1854 Search Results for “”
Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (“NASH”), a liver disease with high unmet medical need. In March 2024, the Company announced that Rezdiffra™ (resmetirom) has been granted accelerated approval by the U.S. Food and Drug Administration in conjunction with diet…
Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying drivers of disease.
Ichor Holdings, Ltd. (“Ichor” or “The Company”) is a leader in the design, engineering and manufacturing of critical fluid delivery subsystems and components primarily for semiconductor capital equipment. Ichor’s primary product offerings include gas and chemical delivery systems and subsystems, collectively known as fluid delivery systems and subsystems, which are key elements of the process…
Apogee Therapeutics, Inc. (“Apogee” or the “Company”) (NASDAQ: APGE) is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (“AD”), asthma, chronic obstructive pulmonary disease (“COPD”) and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting…
MicroStrategy (MSTR) considers itself the world’s first Bitcoin development company. They are a publicly-traded operating company committed to the continued development of the bitcoin network through activities in the financial markets, advocacy and technology innovation. As an operating business, they are able to use cashflows as well as proceeds from equity and debt financings to…
NAPCO Security Technologies, Inc. (“NAPCO” or “The Company”) (NASDAQ: NSSC) is one of the leading manufacturers and designers of high-tech electronic security devices, wireless recurring communication services for intrusion and fire alarm systems as well as a provider of school safety solutions. The Company consists of four Divisions: NAPCO, plus three wholly-owned subsidiaries: Alarm Lock,
Autovista is a leading European and Australian provider of data, analytics and industry insights to the automotive value chain: Vehicle Manufacturing, Leasing Finance, Insurance, Dealerships and Bodyshops. Autovista owns a number of highly respected automotive brands, including Autovista, Eurotax, Glasss, Rødboka and Schwacke. Autovista is headquartered in London, United Kingdom.
Janux Therapeutics, Inc. (“Janux” or “The Company”) (NASDAQ: JANX) is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system…
Humacyte, Inc. (“Humacyte”) (NASDAQ: HUMA) is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. Humacyte is leveraging its novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for…
Celldex Therapeutics, Inc. (“Celldex” or “The Company”) (NASDAQ: CLDX) is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Celldex’s pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve…
Arcutis Biotherapeutics, Inc. (“Arcutis” or the “Company”) (NASDAQ: ARQT) is commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Their current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions.
Load More